Regeneron Pharmaceuticals Ireland Ltd.
GPTKB entity
Statements (84)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Tarrytown, New York facility
|
| gptkbp:ceo |
Leonard S. Schleifer
|
| gptkbp:clinical_trial |
gptkb:Community_outreach
Cell therapy Data analysis Gene therapy Health economics Ongoing Peer review Research funding Biomarkers Clinical decision-making Clinical trials Evidence-based medicine Precision medicine Research ethics Cost-effectiveness analysis Patient outcomes Patient safety Vaccines Data privacy Clinical guidelines Diagnostics Ethical considerations Public engagement Safety assessments Scientific publications Grant applications Research collaborations Biologics Patient-reported outcomes Informed consent Post-marketing studies Monoclonal antibodies Combination therapies Therapeutics Small molecules Treatment protocols Patient advocacy Phase III trials Clinical pathways Health technology assessment Efficacy studies Longitudinal studies Patient recruitment Regulatory submissions Clinical trial registries Research dissemination Phase I trials Phase II trials Quality of life studies Real-world evidence Patient confidentiality Antibody-drug conjugates Knowledge translation Market access studies |
| gptkbp:collaboration |
Academic institutions
|
| gptkbp:employees |
over 1,000
|
| gptkbp:focus_area |
gptkb:Cardiology
gptkb:Ophthalmology gptkb:Oncology Immunology Rare diseases |
| gptkbp:founded |
gptkb:1988
|
| gptkbp:headcount |
approximately 2,000
|
| gptkbp:headquarters |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Regeneron Pharmaceuticals Ireland Ltd.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:innovation |
gptkb:CRISPR_technology
|
| gptkbp:location |
gptkb:Dublin
|
| gptkbp:market_cap |
over $50 billion
|
| gptkbp:parent_company |
gptkb:Regeneron_Pharmaceuticals,_Inc.
|
| gptkbp:partnership |
gptkb:Sanofi
|
| gptkbp:philanthropy |
gptkb:Regeneron_Foundation
|
| gptkbp:products |
gptkb:Libtayo
gptkb:Dupixent gptkb:Eylea |
| gptkbp:regulatory_compliance |
gptkb:FDA
|
| gptkbp:research_focus |
Genetic medicine
|
| gptkbp:subsidiary |
gptkb:Regeneron_Pharmaceuticals,_Inc.
|
| gptkbp:website |
www.regeneron.com
|
| gptkbp:bfsParent |
gptkb:Regeneron_Pharmaceuticals,_Inc.
|
| gptkbp:bfsLayer |
5
|